• Something wrong with this record ?

Valsartan Prevented Neointimal Hyperplasia and Inhibited SRSF1 Expression and the TLR4-iNOS-ERK-AT1 Receptor Pathway in the Balloon-injured Rat Aorta

Y. Li, J. Guo, H. Yu, X. Liu, J. Zhou, X. Chu, Q. Xu, T. Sun, L. Peng, X. Yang, X. Tang

. 2021 ; 70 (4) : 533-542. [pub] 20210601

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22007913

Valsartan has the potential to attenuate neointimal hyperplasia and to suppress the inflammatory response. This study aimed to evaluate the role of valsartan in neointimal hyperplasia and the toll-like receptor 4 (TLR4)-nitric oxide synthase (NOS) pathway in the balloon-injured rat aorta.Forty-eight Wistar rats were randomly allocated to three groups: sham control (control), balloon-injured group (surgery), and balloon-injured+valsartan-treated group (valsartan). Rats were killed at 14 and 28 days after balloon-injury, and then the aortic tissues were collected for morphometric analysis as well as for measurements of the mRNA or protein expression of angiotensin II, angiotensin II type 1 (AT1) receptor, angiotensin II type 2 (AT2) receptor, TLR4, endothelial nitric oxide synthase (eNOS), inducible NOS (iNOS), serine/arginine-rich splicing factor 1(SRSF1) and extracellular signal regulated kinase (ERK). Valsartan at a dose of 20 mg/kg/day markedly decreased neointimal hyperplasia in the aorta of balloon-injured rats, and significantly reduced the mRNA or protein expression of TLR4, AT1 receptor, SRSF1 and phosphorylated-ERK (p-ERK) as well as the aortic levels of iNOS (all p < 0.05). Moreover, valsartan increased the eNOS level and AT2 receptor mRNA and protein expression levels (all p < 0.05). Valsartan prevented neointimal hyperplasia and inhibited SRSF1 expression and the TLR4-iNOS-ERK-AT1 receptor pathway in the balloon-injured rat aorta.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22007913
003      
CZ-PrNML
005      
20220323102115.0
007      
ta
008      
220309s2021 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934579 $2 doi
035    __
$a (PubMed)34062069
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Li, Yonghong $u Department of Cardiology, Affilicated Hospital of Qingdao University, Qingdao, China
245    10
$a Valsartan Prevented Neointimal Hyperplasia and Inhibited SRSF1 Expression and the TLR4-iNOS-ERK-AT1 Receptor Pathway in the Balloon-injured Rat Aorta / $c Y. Li, J. Guo, H. Yu, X. Liu, J. Zhou, X. Chu, Q. Xu, T. Sun, L. Peng, X. Yang, X. Tang
504    __
$a Literatura
520    9_
$a Valsartan has the potential to attenuate neointimal hyperplasia and to suppress the inflammatory response. This study aimed to evaluate the role of valsartan in neointimal hyperplasia and the toll-like receptor 4 (TLR4)-nitric oxide synthase (NOS) pathway in the balloon-injured rat aorta.Forty-eight Wistar rats were randomly allocated to three groups: sham control (control), balloon-injured group (surgery), and balloon-injured+valsartan-treated group (valsartan). Rats were killed at 14 and 28 days after balloon-injury, and then the aortic tissues were collected for morphometric analysis as well as for measurements of the mRNA or protein expression of angiotensin II, angiotensin II type 1 (AT1) receptor, angiotensin II type 2 (AT2) receptor, TLR4, endothelial nitric oxide synthase (eNOS), inducible NOS (iNOS), serine/arginine-rich splicing factor 1(SRSF1) and extracellular signal regulated kinase (ERK). Valsartan at a dose of 20 mg/kg/day markedly decreased neointimal hyperplasia in the aorta of balloon-injured rats, and significantly reduced the mRNA or protein expression of TLR4, AT1 receptor, SRSF1 and phosphorylated-ERK (p-ERK) as well as the aortic levels of iNOS (all p < 0.05). Moreover, valsartan increased the eNOS level and AT2 receptor mRNA and protein expression levels (all p < 0.05). Valsartan prevented neointimal hyperplasia and inhibited SRSF1 expression and the TLR4-iNOS-ERK-AT1 receptor pathway in the balloon-injured rat aorta.
650    _2
$a blokátory receptoru 1 pro angiotenzin II $x farmakologie $7 D047228
650    _2
$a zvířata $7 D000818
650    _2
$a aorta $x účinky léků $x enzymologie $x patologie $7 D001011
650    _2
$a nemoci aorty $x farmakoterapie $x enzymologie $x genetika $x patologie $7 D001018
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a extracelulárním signálem regulované MAP kinasy $x metabolismus $7 D048049
650    _2
$a hyperplazie $7 D006965
650    _2
$a mužské pohlaví $7 D008297
650    12
$a neointima $7 D058426
650    _2
$a synthasa oxidu dusnatého, typ II $x metabolismus $7 D052247
650    _2
$a fosforylace $7 D010766
650    _2
$a potkani Wistar $7 D017208
650    _2
$a receptor angiotensinu typ 1 $x genetika $x metabolismus $7 D044140
650    _2
$a serin-arginin sestřihové faktory $x metabolismus $7 D000068103
650    _2
$a signální transdukce $7 D015398
650    _2
$a toll-like receptor 4 $x genetika $x metabolismus $7 D051197
650    _2
$a valsartan $x farmakologie $7 D000068756
650    _2
$a poranění cév $x farmakoterapie $x enzymologie $x genetika $x patologie $7 D057772
655    _2
$a časopisecké články $7 D016428
700    1_
$a Guo, Junjie $u Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China
700    1_
$a Yu, Haichu $u Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China
700    1_
$a Liu, Xin $u Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China
700    1_
$a Zhou, Jingwei $u Department of Emergency, Affiliated Hospital of Qingdao University, Qingdao, China
700    1_
$a Chu, Xianming $u Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China
700    1_
$a Xu, Qingke $u Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China
700    1_
$a Sun, Tingru $u Department of Cardiology, Zibo First Hospital, Zibo, China
700    1_
$a Peng, Liang $u Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China
700    1_
$a Yang, Xi $u Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China
700    1_
$a Tang, Xilong $u Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 70, č. 4 (2021), s. 533-542
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34062069 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20220309 $b ABA008
991    __
$a 20220323102110 $b ABA008
999    __
$a ok $b bmc $g 1773043 $s 1159106
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 70 $c 4 $d 533-542 $e 20210601 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20220309

Find record

Citation metrics

Archiving options